Pharmacokinetics of intravenous etoposide in patients with breast cancer: Influence of dose escalation and cyclophosphamide and doxorubicin coadministration

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 366, Issue 3, 2002, Pages 218-225

  Busse, Dagmar ^a   Würthwein, Gudrun ^b   Hinske, Christiane ^b   Hempel, Georg ^b   Fromm, Martin F ^a   Eichelbaum, Michel ^a   Kroemer, Heyo K ^c   Busch, Friedrich W ^d  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d Klinikum Hof   (Germany)

Author keywords

Dose dependency; Drug interactions; Etoposide; Pharmacokinetics; Variability

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BLOOD SAMPLING; BREAST CARCINOMA; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG INFUSION; DRUG MEGADOSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ETOPOSIDE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED;

EID: 0036038942     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-002-0594-2     Document Type: Article

References (49)

1. Etoposide pharmacokinetics in patients with normal and abnormal organ function
2. High-dose cyclosporine with etoposide - Toxicity and pharmacokinetic interaction in children with solid tumors
3. Steady-state levels and bone marrow toxicity of etoposide in children and infants: Does etoposide require age-dependent dose calculation?
4. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
5. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer
6. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism
7. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group
8. Pharmacokinetics of VP16-213 given by different administration methods
9. Pharmacokinetics of etoposide in gestochoriocarcinoma
10. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function
11. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs
12. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: Results of a multicenter study
13. Etoposide: Twenty years later
14. Etoposide pharmacology
15. The importance of drug scheduling in cancer chemotherapy: Etoposide as an example
16. Etoposide: Four decades of development of a topoisomerase II inhibitor
17. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients
18. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration
19. Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics
20. Pharmacokinetics
21. Pharmacokinetics of etoposide after oral and intravenous administration in patients with gastric carcinoma
22. Pharmacokinetics of high-dose etoposide after short-term infusion
23. P-Glycoprotein and pharmacokientics
24. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance
25. Molecular targets in oncology: Implications of the multidrug resistance gene
26. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance
27. Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer
28. Pharmacokinetics of high-dose etoposide
29. Population pharmacokinetics of total and unbound etoposide
30. Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide
31. Pharmacokinetics of etoposide: Correlation of pharmacokinetic parameters with clinical conditions
32. Pharmacologically based dosing of etoposide: A means of safely increasing dose intensity
33. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?
34. Human cytochrome P450 metabolism of teniposide and etoposide
35. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin
36. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4
37. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes
38. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation
39. The physiological function of drug-transporting P-glycoproteins
40. The clinical pharmacology of etoposide
41. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer
42. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team
43. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide
44. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction
45. Relation of systemic exposure to unbound etoposide and hematologic toxicity
46. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay
47. Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide
48. Pharmacokinetics of anticancer drugs in vitro
49. Simulation tool for schedule-dependent etoposide exposure based on pharmacokinetic findings published in the literature